Affimed N.V. Stock
Affimed N.V. Stock
Pros and Cons of Affimed N.V. in the next few years
Pros
Cons
Performance of Affimed N.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Affimed N.V. | - | - | - | - | - | - | - |
| Formycon AG | -2.760% | -14.009% | -12.787% | -39.545% | -28.495% | -39.728% | 22.769% |
| MagForce AG | - | -42.857% | 0.000% | -16.667% | 150.000% | -99.952% | -99.958% |
| Biofrontera AG | -9.150% | -2.959% | -8.123% | -72.552% | -19.410% | -86.446% | -94.851% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon an initial overview of the financials of Affimed, a company within the Biotechnology & Medical Research industry marked with US symbol AFMD, one may observe an interesting financial landscape. Although the company has experienced considerable net losses over the past three years, it maintains a substantial amount of cash on hand and continues to invest in research and development. Despite these investments, the company has yet to generate profits. A deep analysis of the company's financials may offer more insight.
In conclusion, Affimed's financial landscape displays both positives and negatives. The company benefits from a strong cash position, growing revenue, and substantial investments in research and development. However, it grapples with recurring net losses, high operating expenses, and negative free cash flow. Potential investors should consider these factors in their analysis and further investigate Affimed's prospects within the competitive Biotechnology & Medical Research industry.
Comments